EA201290195A1 - Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности - Google Patents
Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточностиInfo
- Publication number
- EA201290195A1 EA201290195A1 EA201290195A EA201290195A EA201290195A1 EA 201290195 A1 EA201290195 A1 EA 201290195A1 EA 201290195 A EA201290195 A EA 201290195A EA 201290195 A EA201290195 A EA 201290195A EA 201290195 A1 EA201290195 A1 EA 201290195A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- kidney damage
- compositions
- methods
- immunoglobulin
- factor
- Prior art date
Links
- 230000006378 damage Effects 0.000 title abstract 3
- 210000003734 kidney Anatomy 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 201000006370 kidney failure Diseases 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000009075 Angiopoietin-2 Human genes 0.000 abstract 1
- 108010048036 Angiopoietin-2 Proteins 0.000 abstract 1
- 102000000905 Cadherin Human genes 0.000 abstract 1
- 108050007957 Cadherin Proteins 0.000 abstract 1
- 102100035654 Cathepsin S Human genes 0.000 abstract 1
- 108090000613 Cathepsin S Proteins 0.000 abstract 1
- 102000006818 Cell Adhesion Molecule-1 Human genes 0.000 abstract 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004420 Creatine Kinase Human genes 0.000 abstract 1
- 108010042126 Creatine kinase Proteins 0.000 abstract 1
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 229920002971 Heparan sulfate Polymers 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102000011695 Matrix Metalloproteinase 10 Human genes 0.000 abstract 1
- 108010076497 Matrix Metalloproteinase 10 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 102100036154 Platelet basic protein Human genes 0.000 abstract 1
- 101710195957 Platelet basic protein Proteins 0.000 abstract 1
- 102000004211 Platelet factor 4 Human genes 0.000 abstract 1
- 108090000778 Platelet factor 4 Proteins 0.000 abstract 1
- 206010061481 Renal injury Diseases 0.000 abstract 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 abstract 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 abstract 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 abstract 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 abstract 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 abstract 1
- 101710170091 Transmembrane glycoprotein NMB Proteins 0.000 abstract 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 abstract 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000000104 diagnostic biomarker Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- -1 matrilisin Proteins 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 239000003900 neurotrophic factor Substances 0.000 abstract 1
- 239000000092 prognostic biomarker Substances 0.000 abstract 1
- 229940072041 transforming growth factor beta 2 Drugs 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25915509P | 2009-11-07 | 2009-11-07 | |
| US25916209P | 2009-11-07 | 2009-11-07 | |
| US25913509P | 2009-11-07 | 2009-11-07 | |
| US25913709P | 2009-11-07 | 2009-11-07 | |
| US25915709P | 2009-11-07 | 2009-11-07 | |
| US25915209P | 2009-11-07 | 2009-11-07 | |
| US25916109P | 2009-11-07 | 2009-11-07 | |
| US25914509P | 2009-11-07 | 2009-11-07 | |
| US25915109P | 2009-11-07 | 2009-11-07 | |
| US25915609P | 2009-11-07 | 2009-11-07 | |
| US25914709P | 2009-11-07 | 2009-11-07 | |
| US25914809P | 2009-11-07 | 2009-11-07 | |
| US25913909P | 2009-11-07 | 2009-11-07 | |
| US25915909P | 2009-11-07 | 2009-11-07 | |
| US25913609P | 2009-11-07 | 2009-11-07 | |
| US25915309P | 2009-11-07 | 2009-11-07 | |
| US25916009P | 2009-11-07 | 2009-11-07 | |
| US28592809P | 2009-12-11 | 2009-12-11 | |
| US28592909P | 2009-12-11 | 2009-12-11 | |
| US32072310P | 2010-04-03 | 2010-04-03 | |
| US34654710P | 2010-05-20 | 2010-05-20 | |
| US34655110P | 2010-05-20 | 2010-05-20 | |
| PCT/US2010/055721 WO2011057138A1 (en) | 2009-11-07 | 2010-11-05 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201290195A1 true EA201290195A1 (ru) | 2012-12-28 |
Family
ID=43970376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201290195A EA201290195A1 (ru) | 2009-11-07 | 2010-11-05 | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP2496258B1 (https=) |
| JP (2) | JP2013510321A (https=) |
| CN (2) | CN102711827B (https=) |
| AU (2) | AU2010314999B2 (https=) |
| CA (1) | CA2779905A1 (https=) |
| EA (1) | EA201290195A1 (https=) |
| MX (1) | MX2012005210A (https=) |
| NZ (2) | NZ600160A (https=) |
| WO (1) | WO2011057138A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013023233A1 (en) * | 2011-08-12 | 2013-02-21 | Alfred Health | Method for diagnosis, prognosis or treatment of acute coronary syndrome (acs) comprising measurement of plasma concentration of macrophage migration inhibitory factor (mif) |
| WO2013096740A1 (en) * | 2011-12-21 | 2013-06-27 | Alere San Diego Inc. | Methods and compositions for assigning likelihood of chronic kidney disease progression |
| CA2965153C (en) | 2014-10-20 | 2023-10-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| WO2017101873A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗放射性和化学性损伤的方法 |
| JP6876066B2 (ja) | 2015-12-18 | 2021-05-26 | タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ | 子宮膣部びらんを予防及び治療するための方法 |
| CN107345968A (zh) * | 2016-05-05 | 2017-11-14 | 中国医学科学院基础医学研究所 | Cecam1蛋白作为血清标记物在诊断肝脏疾病中的用途 |
| CN108210894A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗病理性肾组织损伤的药物及其用途 |
| US11154595B2 (en) | 2016-12-15 | 2021-10-26 | Talengen International Limited | Method for preventing and treating pulmonary fibrosis |
| EP4063853A1 (en) | 2017-01-12 | 2022-09-28 | Astute Medical, Inc. | Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| EP4071480A1 (en) * | 2021-04-09 | 2022-10-12 | Fundació Ace. Institut Català de Neurociències Aplicades | Cerebrospinal fluid biomarker for alzheimer's disease |
| EP4573371A2 (en) * | 2022-08-19 | 2025-06-25 | The Johns Hopkins University | Diagnosis and treatment of acute kidney injury |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| AU1772992A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| JP3290988B2 (ja) | 1991-04-11 | 2002-06-10 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | 多重リガンドを同時検出する新規接合体及び検定法 |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| JP2007078705A (ja) * | 1997-04-04 | 2007-03-29 | Seikagaku Kogyo Co Ltd | ヘパラン硫酸の定量方法及び定量キット |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| ATE376187T1 (de) * | 1998-12-21 | 2007-11-15 | Univ Monash | Nachweis von erkrankungen der nieren und behandlung |
| US7482135B2 (en) * | 2000-05-17 | 2009-01-27 | Nederlandse Organisatie Voor Toegepast | Proteolytic enzymes in urine as diagnostic parameters in diseases involving matrix remodelling |
| US20030003588A1 (en) * | 2001-06-28 | 2003-01-02 | Comper Wayne D. | Method for kidney disease detection by protein profiling |
| US7560244B2 (en) * | 2003-06-04 | 2009-07-14 | Joslin Diabetes Center, Inc. | Method of evaluating a subject for risk or predisposition of reduced renal function over time |
| AU2005322410B2 (en) * | 2004-11-30 | 2011-11-10 | Amgen Fremont Inc. | Antibodies directed to GPNMB and uses thereof |
| EP1808694A1 (en) * | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| WO2008133641A2 (en) * | 2006-10-11 | 2008-11-06 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| JP2008118915A (ja) * | 2006-11-10 | 2008-05-29 | Kazuto Nishio | 胃癌高発現遺伝子特定による胃癌診断および創薬への利用 |
| WO2008060607A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
| ES2836218T3 (es) * | 2008-10-21 | 2021-06-24 | Astute Medical Inc | Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| US8460884B2 (en) * | 2008-11-05 | 2013-06-11 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Use of hematopoietic growth factor inducible neurokinin-1 (HGFIN) as a biomarker for renal injury or renal disease |
-
2010
- 2010-11-05 NZ NZ600160A patent/NZ600160A/en not_active IP Right Cessation
- 2010-11-05 NZ NZ624614A patent/NZ624614A/en not_active IP Right Cessation
- 2010-11-05 WO PCT/US2010/055721 patent/WO2011057138A1/en not_active Ceased
- 2010-11-05 AU AU2010314999A patent/AU2010314999B2/en not_active Ceased
- 2010-11-05 EP EP10829191.5A patent/EP2496258B1/en not_active Not-in-force
- 2010-11-05 CN CN201080057014.7A patent/CN102711827B/zh not_active Expired - Fee Related
- 2010-11-05 MX MX2012005210A patent/MX2012005210A/es not_active Application Discontinuation
- 2010-11-05 CN CN201510259537.4A patent/CN104914247B/zh not_active Expired - Fee Related
- 2010-11-05 EA EA201290195A patent/EA201290195A1/ru unknown
- 2010-11-05 CA CA2779905A patent/CA2779905A1/en not_active Abandoned
- 2010-11-05 EP EP16196505.8A patent/EP3153863B1/en active Active
- 2010-11-05 JP JP2012538050A patent/JP2013510321A/ja active Pending
-
2014
- 2014-09-12 AU AU2014224137A patent/AU2014224137A1/en not_active Abandoned
-
2016
- 2016-09-16 JP JP2016181599A patent/JP6609533B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014224137A1 (en) | 2014-10-02 |
| JP2013510321A (ja) | 2013-03-21 |
| WO2011057138A1 (en) | 2011-05-12 |
| HK1214864A1 (zh) | 2016-08-05 |
| JP6609533B2 (ja) | 2019-11-20 |
| NZ624614A (en) | 2015-10-30 |
| EP3153863B1 (en) | 2020-04-01 |
| EP2496258A4 (en) | 2013-06-26 |
| AU2010314999A1 (en) | 2012-06-14 |
| HK1170955A1 (zh) | 2013-03-15 |
| JP2017026627A (ja) | 2017-02-02 |
| MX2012005210A (es) | 2012-08-03 |
| EP3153863A1 (en) | 2017-04-12 |
| CA2779905A1 (en) | 2011-05-12 |
| NZ600160A (en) | 2014-05-30 |
| EP2496258A1 (en) | 2012-09-12 |
| CN102711827A (zh) | 2012-10-03 |
| CN104914247A (zh) | 2015-09-16 |
| EP2496258B1 (en) | 2016-11-02 |
| AU2010314999B2 (en) | 2014-06-26 |
| CN104914247B (zh) | 2018-04-17 |
| CN102711827B (zh) | 2015-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290195A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| MX342967B (es) | Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal. | |
| EA201290711A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EA201291314A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EP2767833A3 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| EP2585827A4 (en) | METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency | |
| EA201490384A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| WO2010022210A3 (en) | Diagnosis and monitoring of renal failure using peptide biomarkers | |
| JP2009501333A5 (https=) | ||
| EA201290056A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| MX2011004767A (es) | Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal. | |
| ATE456055T1 (de) | Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden | |
| RU2018139780A (ru) | Способы и наборы диагностики и стратификации риска пациентов с ишемией | |
| EA201490105A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| WO2009152607A8 (en) | Methods and kits for diagnosing neurodegenerative disease | |
| EA201290192A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| WO2007106224A3 (en) | Method of detecting or diagnosing of a neurodegenerative disease or condition | |
| WO2008021290A8 (en) | Organ-specific proteins and methods of their use | |
| MY162697A (en) | Methods, devices and kits for detecting or monitoring acute kidney injury | |
| WO2011035012A3 (en) | Methods and compositions for diagnosing heart failure | |
| Segarra-Medrano et al. | Value of urinary levels of interleukin-6, epidermal growth factor, monocyte chemoattractant protein type 1 and transforming growth factor β1 in predicting the extent of fibrosis lesions in kidney biopsies of patients with IgA nephropathy | |
| EA201290627A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| Eastwood et al. | Impact of kidney function on cardiovascular risk and mortality: a comparison of South Asian and European cohorts | |
| Javanmardi et al. | Diagnostic value of cystatin C for diagnosis of early renal damages in type 2 diabetic mellitus patients: The first experience in Iran | |
| EA201290106A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности |